BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26428229)

  • 1. [KRAS mutations and survival after resection of colorectal liver metastases].
    Mroczkowski P; Bruns CJ
    Chirurg; 2015 Nov; 86(11):1071. PubMed ID: 26428229
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Poorest Survival Outcomes in Patients with Right Colon Cancer with KRAS Mutation After Simultaneous Curative-Intent Surgery for Colorectal Cancer Liver Metastases.
    Kim HS; Kim NK
    Ann Surg Oncol; 2020 Dec; 27(13):5159-5160. PubMed ID: 32813206
    [No Abstract]   [Full Text] [Related]  

  • 3. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer.
    Steele CW; Whittle T; Smith JJ
    Chin Clin Oncol; 2019 Oct; 8(5):53. PubMed ID: 31597434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.
    Serenari M; Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
    Dig Surg; 2018; 35(4):303-310. PubMed ID: 29032374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases.
    Shindoh J
    Chin Clin Oncol; 2019 Oct; 8(5):47. PubMed ID: 31500425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
    O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
    Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis.
    Moro A; Mehta R; Tsilimigras DI; Sahara K; Paredes AZ; Bagante F; Guglielmi A; Alexandrescu S; Poultsides GA; Sasaki K; Aucejo FN; Pawlik TM
    Surgery; 2020 Sep; 168(3):497-503. PubMed ID: 32675031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
    Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
    Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.
    Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I
    Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [I. Impact of Surgical Margin Status on Outcomes of Surgical Resection for Colorectal Liver Metastases].
    Hosokawa I; Adam R; Miyazaki M; Shimizu H; Koda K; Ohtsuka M
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1417-1422. PubMed ID: 30382036
    [No Abstract]   [Full Text] [Related]  

  • 14. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
    Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
    Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases.
    Margonis GA; Sasaki K; Kim Y; Samaha M; Buettner S; Amini N; Antoniou E; Pawlik TM
    J Gastrointest Surg; 2016 Nov; 20(11):1821-1829. PubMed ID: 27384430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM
    J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.